View in EDS

Effects of Korean Red Ginseng (Panax ginseng C.A. Meyer) on Menopausal Symptoms in Premenopausal Women After Gynecologic Cancer Surgery: A Double-Blind, Randomized Controlled Trial

Saved in:
Bibliographic Details
Title: Effects of Korean Red Ginseng (Panax ginseng C.A. Meyer) on Menopausal Symptoms in Premenopausal Women After Gynecologic Cancer Surgery: A Double-Blind, Randomized Controlled Trial
Authors: Young Shin Chung, Sunghoon Kim, In Ok Lee, Young Tae Kim, Jung Yun Lee, Eun Ji Nam, Sang Wun Kim
Contributors: Young Shin Chung, In Ok Lee, Jung-Yun Lee, Eun Ji Nam, Sang Wun Kim, Young Tae Kim, Sunghoon Kim, Kim, Sang Wun
Source: The Journal of Alternative and Complementary Medicine. 27:66-72
Publisher Information: Mary Ann Liebert Inc, 2021.
Publication Year: 2021
Subject Terms: Adult, Genital Neoplasms, Female, premenopausal women, Hot Flashes / drug therapy, Panax, surgical menopause symptoms, survival, 03 medical and health sciences, 0302 clinical medicine, Premenopause / physiology, Double-Blind Method, Female / surgery, Humans, Postoperative Period, Korean red ginseng, Plant Extracts, Middle Aged, 3. Good health, Premenopause, Hot Flashes, Plant Extracts / therapeutic use, gynecologic cancer, Female, Genital Neoplasms, Menopause, Menopause / physiology
Description: Objectives: Korean red ginseng (KRG) has been widely used as an alternative medicine to relieve menopausal symptoms. However, there is still a lack of clinical studies showing the effects of KRG on menopausal symptoms after gynecologic cancer surgery. Therefore, the authors investigated the effects of KRG on surgical menopause symptoms in premenopausal women with gynecologic cancer. Design: A double-blind, randomized, placebo-controlled clinical trial was conducted. Settings/Location: The study was performed at Severance Hospital at the Yonsei University College of Medicine in Seoul, Korea. Subjects: Fifty-five premenopausal women diagnosed with gynecologic cancer were enrolled in the study. Interventions: Patients were randomly assigned to a KRG (n = 29) or a placebo control group (n = 26). Subjects were administered either KRG (a total of 3 g per day) or placebo supplements for 12 weeks. Outcome measures: Patients' physical measurements (height, weight, and blood pressure) and blood samples (lipid profiles, hormone profiles, biochemical profiles, and neutrophil-to-lymphocyte ratio) at baseline and at 12 weeks were compared. Changes in menopausal symptoms based on the Menopause Rating Scale (MRS) were also compared between these two time points and two groups. Results: After 12 weeks, the MRS score was significantly reduced in each group (p = 0.001 and p = 0.001, respectively), but there were no significant differences between the two groups (p = 0.661). No adverse events were observed in either group. After comparing 11 MRS symptoms between the two groups, the KRG group seemed to be superior to the placebo group on the subscale of sexual complaints (p
Document Type: Article
Language: English
ISSN: 1557-7708
1075-5535
DOI: 10.1089/acm.2019.0429
Access URL: https://pubmed.ncbi.nlm.nih.gov/33216632
https://pubmed.ncbi.nlm.nih.gov/33216632/
https://www.liebertpub.com/doi/full/10.1089/acm.2019.0429
https://www.ncbi.nlm.nih.gov/pubmed/33216632
http://www.liebertpub.com/doi/full/10.1089/acm.2019.0429
https://ir.ymlib.yonsei.ac.kr/handle/22282913/182064
Rights: Mary Ann Liebert TDM
CC BY NC ND
Accession Number: edsair.doi.dedup.....5dfcec8dd3ca5b545fb871a889ba465b
Database: OpenAIRE
Description
Abstract:Objectives: Korean red ginseng (KRG) has been widely used as an alternative medicine to relieve menopausal symptoms. However, there is still a lack of clinical studies showing the effects of KRG on menopausal symptoms after gynecologic cancer surgery. Therefore, the authors investigated the effects of KRG on surgical menopause symptoms in premenopausal women with gynecologic cancer. Design: A double-blind, randomized, placebo-controlled clinical trial was conducted. Settings/Location: The study was performed at Severance Hospital at the Yonsei University College of Medicine in Seoul, Korea. Subjects: Fifty-five premenopausal women diagnosed with gynecologic cancer were enrolled in the study. Interventions: Patients were randomly assigned to a KRG (n = 29) or a placebo control group (n = 26). Subjects were administered either KRG (a total of 3 g per day) or placebo supplements for 12 weeks. Outcome measures: Patients' physical measurements (height, weight, and blood pressure) and blood samples (lipid profiles, hormone profiles, biochemical profiles, and neutrophil-to-lymphocyte ratio) at baseline and at 12 weeks were compared. Changes in menopausal symptoms based on the Menopause Rating Scale (MRS) were also compared between these two time points and two groups. Results: After 12 weeks, the MRS score was significantly reduced in each group (p = 0.001 and p = 0.001, respectively), but there were no significant differences between the two groups (p = 0.661). No adverse events were observed in either group. After comparing 11 MRS symptoms between the two groups, the KRG group seemed to be superior to the placebo group on the subscale of sexual complaints (p
ISSN:15577708
10755535
DOI:10.1089/acm.2019.0429